All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Binimetinib Improves PFS in NRAS-Mutant Melanoma

December 16th 2015

The MEK inhibitor binimetinib has demonstrated an improvement in progression-free survival compared with dacarbazine in patients with advanced NRAS-mutant melanoma.

Adjuvant Hormonal Therapy Linked to Improved Outcomes in Ovarian Cancer

December 16th 2015

Adjuvant hormone therapy was associated with a 37% reduction in the risk of death in women with epithelial ovarian cancer.

A Cancer Talk With Pulitzer Prize Winner Siddhartha Mukherjee

December 16th 2015

Siddhartha Mukherjee, MD, discussed new developments in cancer treatment and the potential for conquering this scourge once and for all.

FDA Delays Decision on Rociletinib in NSCLC

December 16th 2015

The FDA has extended the review period for rociletinib in patients with EGFR T790M-positive non–small cell lung cancer by 3 months, to allow ample time to review additional data.

Advanced Prostate Cancer Clinics Make Inroads in Practices

December 15th 2015

Gary Kirsh, MD, president of The Urology Group and LUGPA, Kirsh provides insight on treating prostate cancer within the context of urology, as well as the benefits of a multidisciplinary approach.

Urologists Adapt Treatment Paradigm to Incorporate Novel Agents in mCRPC

December 15th 2015

Raoul S. Concepcion, MD, FACS, discussed novel therapies for treating mCRPC and deciding which patients are appropriate candidates.

Prostate Cancer Guidelines Lack Molecular Test Recommendations

December 15th 2015

When compared with the National Comprehensive Cancer Network (NCCN) breast cancer guidelines, the corresponding prostate cancer guidelines fall short in one distinct characteristic—the lack of a molecular test in tissue-based platforms at this point in time.

Multiple Trials Explore Radium-223 Combinations for mCRPC

December 15th 2015

Clinical trials are now assessing how to best use radium-223 (Xofigo) in combination with androgen inhibitors, following the rapid approval of several agents for men with castration-resistant prostate cancer.

Multi-Epitope Vaccine Granted Orphan Designation for Ovarian Cancer

December 14th 2015

The FDA has granted an orphan drug designation to the multi-epitope folate receptor alpha (FRα) vaccine TPIV 200 as a treatment for patients with ovarian cancer.

FDA Approves Cooling Cap to Reduce Alopecia During Chemotherapy

December 14th 2015

The Dignitana DigniCap Cooling System, a computer-controlled device aimed to reduce the severity and frequency of hair loss in patients who receive neoadjuvant or adjuvant chemotherapy for breast cancer, has been cleared by the FDA as the first cooling cap for use in the United States.

FDA Approves Alectinib for ALK-Positive NSCLC

December 11th 2015

The FDA has granted an accelerated approval to alectinib as a treatment for patients with metastatic ALK-positive non–small cell lung cancer following progression on crizotinib.

Expert Describes Discouraging Neoadjuvant Data in HER2+ Breast Cancer

December 10th 2015

Gunter von Minckwitz, MD, discusses less-than-encouraging results and what next steps lie ahead in neoadjuvant therapy regimens for HER2-positive breast cancer.

FDA Grants Priority Review to Palbociclib in Pretreated HR+/HER2- Breast Cancer

December 10th 2015

The FDA has granted a priority review to a supplemental new drug application for palbociclib (Ibrance) for use in combination with fulvestrant in pretreated patients with HR-positive, HER2-negative metastatic breast cancer.

Prophylactic Intervention Improves Cardiac Safety in HER2-Positive Breast Cancer

December 10th 2015

Prophylactic administration of standard heart failure medications helped preserve left ventricular ejection fraction in patients treated with trastuzumab for HER2-positive metastatic breast cancer.

FDA Approves Bendamustine Hydrochloride for CLL, NHL

December 9th 2015

The FDA has approved a rapid infusion formulation of bendamustine under the trade name Bendeka for the treatment of patients with chronic lymphocytic leukemia or indolent B-cell non-Hodgkin lymphoma that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.

Short Course Radiation Treatment for Breast Cancer

December 9th 2015

Active research and advancements in the field focuses on lessening the burden of radiation treatment while still maintaining acceptable cosmetic outcomes for patients with breast cancer.

FDA Grants Crizotinib Priority Review for ROS1-positive NSCLC

December 9th 2015

The FDA has granted a priority review to crizotinib as a treatment for patients with ROS1-positive metastatic non–small cell lung cancer.

Immunotherapy Shows Early Promise in Advanced Sarcomas

December 7th 2015

Phase Ib/II research has shown promise for adoptive cellular therapy combined with ipilimumab in patients with advanced sarcomas.

Adding Olaratumab to Chemo Improves Survival in Soft Tissue Sarcoma

December 4th 2015

Combining olaratumab with doxorubicin reduced the risk of death by 54% versus doxorubicin alone in patients with advanced soft tissue sarcoma.

Hudis on ExteNET, APHINITY, and What's Next for Adjuvant HER2+ Breast Cancer

December 4th 2015

Clifford Hudis, MD, discusses the evolving adjuvant therapy options in HER2-positive breast cancer.

NEXT PAGE
PREVIOUS PAGE
x